Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cellicon Lab Inc. has 1 pending office action currently active in the Biotechnology & Pharmaceuticals technology area. The prosecution of this portfolio is centralized, involving 1 distinct examiner and 1 distinct art unit. This structure implies that the company's current legal efforts are focused on a specific subset of biotechnology. The involvement of a single art unit indicates that the technical review is confined to a single specialized group.
CHANDRAKUMAR, NIZAL S is the busiest examiner for the portfolio, with 1 pending office action assigned. This single examiner is responsible for the entirety of the company's pending workload. Practitioners can observe that the 1 distinct art unit involved defines the administrative variety of the prosecution process. The concentration of the active matter under CHANDRAKUMAR, NIZAL S provides a singular focus for the company's current patenting activities. This alignment between the total pending actions and the busiest examiner's workload shows that the entire active portfolio is under the review of a single individual. The 1 pending office action represents the entirety of the current workload for this entity.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270818 | NOVEL SKIN-PERMEABLE PEPTIDE, COMPOSITION INCLUDING THE SAME FOR SKIN AND MUCOUS MEMBRANE, AND USE THEREOF | CHANDRAKUMAR, NIZAL S | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270818 | NOVEL SKIN-PERMEABLE PEPTIDE, COMPOSITION INCLUDING THE SAME FOR SKIN AND MUCOUS MEMBRANE, AND USE THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | §103Other | Non-Final OA | — | Pending | Jul 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCellicon Lab Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nizal S Chandrakumar has the most, with 1 of Cellicon Lab Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
